MedTrace Logo

Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma

NCT00536913 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2012-04-06

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to compare Symbicort pMDI with and without spacer in terms of steroid potency, improvement of lung function and asthma symptoms in children with asthma (6-11 years).

Conditions

Interventions

DRUG

Budesonide/formoterol pMDI 40/2.25ug + spacer

DRUG

Budesonide/formoterol pMDI 40/2.25 ug

Sponsors & Collaborators

Principal Investigators

  • Tomas Anderson, MD PhD · AstraZeneca

  • Piotr Kuna, MD PhD · Uniwersytecki Spital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
11 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-02-29
Completion
2008-02-29

Countries

  • Hungary
  • Poland
  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00536913 on ClinicalTrials.gov